Can-Fite Biopharma Overview
Valuation check: CANF's PEG ratio is -2.98, below the Healthcare sector average of 2.89.
Get informed when a big investor buys or sells
+ Follow-2.98
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for CANF is -2.98. That is below the Healthcare sector average of 2.89. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CANF currently prints -2.98 for PEG ratio, while the sector average sits near 2.89. That is roughly 203.0% below the sector mean. Large gaps often invite a closer look at Can-Fite Biopharma's growth, margins, and balance sheet.
A PEG ratio of -2.98 for Can-Fite Biopharma is not 'good' or 'bad' on its own. Compare it with the peer average (2.89) and with CANF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting CANF's PEG ratio (-2.98), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
